News briefs from Sanofi, Biogen/SOBI and Novartis
French drug major Sanofi (Euronext: SAN) and subsidiary Genzyme have reported results from pivotal studies - CARE-MS I and CARE-MS II showing that the multiple sclerosis drug Lemtrada (alemtuzumab) was significantly more effective at reducing annualized relapse rates than the comparator Rebif ((77.6% versus 58.7%, p<0.0001), and about 65% of patients on Lemtrada were relapse-free at two years compared to 47% on Rebif (p<0.0001).
In addition, in CARE-MS II, accumulation of disability was significantly slowed in patients receiving Lemtrada versus Rebif (interferon beta-1a). Furthermore, data indicated that patients treated with Lemtrada were significantly more likely to experience improvement in disability scores than those given Rebif suggesting a reversal of disability in some patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze